Nanobiotix Reports Strong H1 2026 Data, Extends Cash Runway to 2029…

Event summary

Promising early results from Phase 1 study of JNJ-1900 (NBTXR3) in NSCLC show 70% one-year overall survival.
€86 million follow-on offering completed in May 2026, extending cash runway into 2029.
FDA cleared protocol amendment for Phase 3 NANORAY-312 study in head and neck cancer.
€110.9 million in cash and cash equivalents as of June 30, 2026.
Phase 2 CONVERGE study in Stage 3 NSCLC shows 85.7% overall response rate.

The big picture

Nanobiotix's H1 2026 update underscores its strategic pivot towards leveraging nanotherapeutic approaches in oncology, backed by strong financial positioning and promising clinical data. The company's collaboration with Johnson & Johnson and regulatory clearances highlight its ability to navigate complex clinical and commercial landscapes. The €86 million raise and extended cash runway position Nanobiotix to sustain its pipeline through 2029, a critical period for its lead asset JNJ-1900 (NBTXR3).

What we're watching

Clinical Progress: Whether the promising Phase 1 and Phase 2 results for JNJ-1900 (NBTXR3) will translate into successful Phase 3 outcomes.
Financial Strategy: How Nanobiotix will allocate its extended cash runway to support both current and next-wave nanotherapeutic platforms.
Regulatory Dynamics: The impact of the FDA's protocol amendment on the timeline and success of the NANORAY-312 study.